Biocon Biologics secures market access for Yesintek in the US driven by demand from national and commercial formularies
Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent over 100+ million lives in the United States. Express …